Marked improvement in nail psoriasis during treatment with etanercept.

Abstract

Psoriasis is a chronic inflammatory skin condition that affects approximately 3% of the population. Up to 50% of patients with psoriasis have concurrent nail psoriasis, up to 30% of patients with skin psoriasis also have psoriatic arthritis and of these, approximately 80% have nail disease. The treatment of nail psoriasis is often challenging, and there is a need for new therapeutic options. Effective biological agents used in the treatment of moderate to severe chronic plaque psoriasis may represent a new therapeutic modality for this disease. A case of rapid improvement is reported in nail psoriasis under etanercept monotherapy with maintained efficacy following the withdrawal of continued therapy.

• Authors: Mercedes Gómez Vázquez, Ramón Navarra Amayuelas
• Journal: Dermatologic therapy (Dermatol Ther) 2011 Sep-Oct Vol. 24 Issue 5 Pg. 498-500 ISSN: 1529-8019 [Electronic] United States
• PMID: 22353156 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2012 Wiley Periodicals, Inc.

Chemical References

• Immunoglobulin G
• Immunologic Factors
• Receptors, Tumor Necrosis Factor
• Etanercept

Topics

• Adult
• Etanercept
• Humans
• Immunoglobulin G (therapeutic use)
• Immunologic Factors (therapeutic use)
• Male
• Nail Diseases (drug therapy)
• Psoriasis (drug therapy)
• Receptors, Tumor Necrosis Factor (therapeutic use)